

Press release from Emotra AB (publ)  
Göteborg, January 10, 2014

## Emotra signs agreement with EPA-SS

**Emotra has signed an agreement with EPA-SS, the Suicide Section of the European Psychiatric Association. The purpose of this agreement is to perform a broad, multi-centre study on Emotra's electrodermal measurement system for the evaluation of suicide risks, and to spread knowledge about this new technique.**

If the results of the study prove to be as anticipated, the parties will organise symposia and consensus meetings as well as training and educational activities during international scientific congresses. Within the European Psychiatric Association, EPA-SS is the individual section having the highest number of members, including scientists and psychiatric specialists, primarily focusing on suicide prevention.

- *This agreement with EPA-SS confirms that the leading figures within suicide research believe in our method and recognise the importance of organising the activities in the best possible way from the very beginning. That EPA-SS is involved in the project is certainly beneficial for Emotra, as we are now two parties who cooperate to present relevant information about the method to the market, says Claes Holmberg, CEO of Emotra AB.*

Emotra plans to involve 15 leading European clinical teams in the evaluation of the use of EDOR over the next two years. To date, Emotra has signed agreements with three of these fifteen clinics, and discussions and negotiations are ongoing with several other groups from different countries. For the purpose of preparing these clinical studies, applications to ethical committees and CE marking are simultaneously being prepared.

At present, Emotra is in the middle of a very dynamic phase, and its activities involve an increasing number of clinical centres. In order to minimise the financial risks, all work is carried out within a small organisation and as cost-effectively as possible. When support for EDOR from these clinical teams has grown sufficiently strong, we will launch the method in Europe.

*For more information, please contact Claes Holmberg, CEO, Emotra AB, at +46 708 25 45 47 or [claes@emotra.se](mailto:claes@emotra.se)*

*or Lars-Håkan Thorell, Head of Research, Emotra AB, at +46 733 95 31 20 or [lars@emotra.se](mailto:lars@emotra.se)*

---

**Emotra AB (publ)** has developed a method – EDOR – of detecting depressed patients who are at risk of committing suicide. In studies encompassing more than 1,000 patients, this method has shown a reliability of approximately 97%. In other words, Emotra's method can determine, with 97% certainty, if a person runs a significantly higher risk of suicide attempt, facilitating decisions about where special suicide prevention measures are needed. EDOR helps the right patients get the care they need.